About

Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology. The new drug GM-XANTHO, developed by Xantho Biotech, is a steroid-free topical ointment for the treatment of atopic dermatitis (AD). The efficacy and safety of GM-XANTHO in patients with atopic dermatitis are currently being studied in a double-blinded, placebo-controlled phase 2a clinical trial, and the interim analysis result will be available in 2023 Q2. We are looking to collaborate with pharmaceutical companies and investors to offer a better drug for AD patients. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization. For more information please visit https://xanthobio.com/en/ About Xantho Biotechnology Co., Ltd. Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology. The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal topical cream which potentially has both therapeutic and preventive effects in inflammatory skin conditions including atopic dermatitis (AD) and plaque psoriasis. GM-XANTHO also has wound healing effect in skin conditions such as pressure ulcer, diabetic wound and burn wound. The IND for AD, plaque psoriasis and pressure ulcer have been approved by the USFDA. We are looking to collaborate with pharmaceutical companies to offer a better drug for AD patients. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization. For more information please visit https://xanthobio.com/en/ About Xantho Biotechnology Co., LTD Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology. The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal topical cream which potentially has both therapeutic and preventive effects in inflammatory skin conditions including atopic dermatitis (AD) and plaque psoriasis. GM-XANTHO also has wound healing effect in skin conditions such as pressure ulcer, diabetic wound and burn wound. The IND for AD, plaque psoriasis and pressure ulcer have been approved by the USFDA. We are looking to collaborate with pharmaceutical companies to offer a better drug for AD patients. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization. For more information please visit https://xanthobio.com/en/ The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal topical cream which potentially has both therapeutic and preventive effects in inflammatory skin conditions including atopic dermatitis (AD) and plaque psoriasis. GM-XANTHO also has wound healing effects in skin conditions such as pressure ulcer and diabetic wound. The IND for AD, plaque psoriasis and pressure ulcer have been approved by the USFDA. The efficacy of GM-XANTHO is currently being studied in a double-blinded, placebo-controlled phase 2a clinical trial in mild-to-moderate AD patients (ClinicalTrials.gov ID NCT04369846). The results of the phase 2a study are expected to be available in 2025Q1. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization. For more information please visit https://xanthobio.com/en/